MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vaughan, R. A.
Right arrow Articles by Dutta, A. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vaughan, R. A.
Right arrow Articles by Dutta, A. K.

Vol. 59, Issue 5, 1157-1164, May 2001

Dual Incorporation of Photoaffinity Ligands on Dopamine Transporters Implicates Proximity of Labeled Domains

Roxanne A. Vaughan, Jon D. Gaffaney, John R. Lever, Maarten E. A. Reith, and Aloke K. Dutta

Department of Biochemistry and Molecular Biology, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota (R.A.V., J.D.G.); Department of Environmental Health Sciences, Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland (J.R.L.); Department of Biomedical and Therapeutic Science, University of Illinois, Peoria, Illinois (M.E.A.R.); and Department of Pharmaceutical Sciences, Wayne State University, Detroit, Michigan (A.K.D.)

We have recently developed novel high-affinity blockers for the dopamine transporter (DAT) by carrying out structure-activity studies of GBR 12909 molecule piperidine analogs. To investigate the molecular basis of binding of these compounds in comparison to known sites of action of GBR 12909, cocaine, and benztropine analogs, we developed a piperidine-based photoaffinity label [125I]4-[2-(diphenylmethoxy)ethyl]-1-[(4-azido- 3-iodophenyl)methyl]-piperidine [125I]AD-96-129), and used proteolysis and epitope-specific immunoprecipitation to identify the protein domains that interact with the ligand. [125I]AD-96-129 became incorporated into two different regions of the DAT primary sequence, an N-terminal site containing transmembrane domains (TMs) 1 to 2, and a second site containing TMs 4 to 6. Both of these regions have been identified previously as sites involved in the binding of other DAT photoaffinity labels. However, in contrast to the previously characterized ligands that showed nearly complete specificity in their binding site incorporation, [125I]AD-96-129 became incorporated into both sites at comparable levels. These results suggest that the two domains may be in close three-dimensional proximity and contribute to binding of multiple uptake blockers. We also found that DATs labeled with [125I]AD-96-129 or other photoaffinity labels displayed distinctive sensitivities to proteolysis of a site in the second extracellular loop, with protease resistance related to the extent of ligand incorporation in the TM4 to 6 region. These differences in protease sensitivity may indicate the relative proximity of the ligands to the protease site or reflect antagonist-induced conformational changes in the loop related to transport inhibition.


Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
V. Murthy, T. J. Martin, S. Kim, H. M. L. Davies, and S. R. Childers
In Vivo Characterization of a Novel Phenylisothiocyanate Tropane Analog at Monoamine Transporters in Rat Brain
J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 587 - 595.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. L. Parnas, J. D. Gaffaney, M. F. Zou, J. R. Lever, A. H. Newman, and R. A. Vaughan
Labeling of Dopamine Transporter Transmembrane Domain 1 with the Tropane Ligand N-[4-(4-Azido-3-[125I]iodophenyl)butyl]-2{beta}-carbomethoxy-3{beta}-(4-chlorophenyl)tropane Implicates Proximity of Cocaine and Substrate Active Sites
Mol. Pharmacol., April 1, 2008; 73(4): 1141 - 1150.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. A. Vaughan, D. S. Sakrikar, M. L. Parnas, S. Adkins, J. D. Foster, R. A. Duval, J. R. Lever, S. S. Kulkarni, and A. Hauck-Newman
Localization of Cocaine Analog [125I]RTI 82 Irreversible Binding to Transmembrane Domain 6 of the Dopamine Transporter
J. Biol. Chem., March 23, 2007; 282(12): 8915 - 8925.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. D. Gaffaney and R. A. Vaughan
Uptake Inhibitors but not Substrates Induce Protease Resistance in Extracellular Loop Two of the Dopamine Transporter
Mol. Pharmacol., March 1, 2004; 65(3): 692 - 701.
[Abstract] [Full Text] [PDF]


Home page
Biophys. JHome page
K. A. Selz, A. J. Mandell, M. F. Shlesinger, V. Arcuragi, and M. J. Owens
Designing Human m1 Muscarinic Receptor-Targeted Hydrophobic Eigenmode Matched Peptides as Functional Modulators
Biophys. J., March 1, 2004; 86(3): 1308 - 1331.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. J. Loland, C. Granas, J. A. Javitch, and U. Gether
Identification of Intracellular Residues in the Dopamine Transporter Critical for Regulation of Transporter Conformation and Cocaine Binding
J. Biol. Chem., January 30, 2004; 279(5): 3228 - 3238.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics